[1] SUNG H,FERLAY J,SIEGEL R L,et al.Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin,2021,71(3):209-249. [2] AMINI L,SILBERT S K,MAUDE S L,et al.Preparing for CAR T cell therapy:patient selection,bridging therapies and lymphodepletion[J]. Nat Rev Clin Oncol,2022,19(5):342-355. [3] SCOVILLE S D,NALIN A P,CHEN L X,et al.Human AML activates the aryl hydrocarbon receptor pathway to impair NK cell development and function[J]. Blood,2018,132(17):1792-1804. [4] SAKAMOTO N,ISHIKAWA T,KOKURA S,et al.Phase I clinical trial of autologous NK cell therapy using novel expansion method in patients with advanced digestive cancer[J]. J Transl Med,2015,13:277. [5] ILIOPOULOU E G,KOUNTOURAKIS P,KARAMOUZIS M V,et al.A phase I trial of adoptive transfer of allogeneic natural killer cells in patients with advanced non-small cell lung cancer[J]. Cancer Immunol Immunother,2010,59(12):1781-1789. [6] PEYTOUR Y,VILLACRECES A,CHEVALEYRE J,et al.Discarded leukoreduction filters:a new source of stem cells for research,cell engineering and therapy?[J]. Stem Cell Res,2013,11(2):736-742. [7] REZWANI M,MAZARZAEI A,ABBASI-MALATI Z, et al.Leukocyte reduction filters are reliable and economic source for natural killer cell preparation[J]. Iran J Immunol,2023,20(1):114-128. [8] GELLER M A,MILLER J S.Use of allogeneic NK cells for cancer immunotherapy[J]. Immunotherapy, 2011,3(12):1445-1459. [9] MATSUBARA H,NIWA A,NAKAHATA T,et al.Induction of human pluripotent stem cell-derived natural killer cells for immunotherapy under chemically defined conditions[J]. Biochem Biophys Res Commun, 2019,515(1):1-8. [10] LIN S J,KUO M L.Cytotoxic function of umbilical cord blood natural killer cells:relevance to adoptive immunotherapy[J]. Pediatr Hematol Oncol,2011,28(8): 640-646. [11] PUERTO-MEREDITH S,SINGOGO E,CHAGOMERANA M,et al.Systematic review of prevalence and risk factors of transfusion transmissible infections among blood donors,and blood safety improvements in Southern Africa[J]. Transfus Med,2023,33(5):355-371. [12] M’BAYA B,JUMBE V,SAMUEL V,et al. Seroprevalence and trends in transfusion transmissible infections among voluntary non-remunerated blood donors at the Malawi Blood Transfusion Service-a time trend study[J]. Malawi Med J,2019,31(2):118-125. [13] SASANI N,ROGHANIAN R,EMTIAZI G,et al.Design and introduction of a rational mechanical eluting system for leukocyte recovery from leukoreduction filters:a cell differential approach[J]. Transfus Clin Biol,2020,27(3):172-178. [14] 陈小林,李冬妹,徐彬,等. 从滤白后的白细胞滤器中回收外周血单个核细胞的可行性研究[J]. 北京医学,2020,42(4):340-343. [15] BOUDREAU G,CARLI C,LAMARCHE C,et al.Leukoreduction system chambers are a reliable cellular source for the manufacturing of T-cell therapeutics[J]. Transfusion,2019,59(4):1300-1311. [16] MALATI Z A,POURFATHOLLAH A A,DABBAGHI R, et al.Evaluation of a new method of leukocyte extractions from the leukoreduction filter[J]. Indian J Hematol Blood Transfus,2023,39(3):478-486. [17] 汤龙海,何红红,黄子逸,等. 两种白细胞滤器获取单个核细胞作为实验研究的生物学功能的比较[J]. 南通大学学报(医学版),2019,39(3):161-165. [18] 张庆利,王琳,黄凯,等. 白细胞滤器中白细胞回收及其细胞生物学特点的研究进展[J]. 国际输血及血液学杂志,2021,44(1):84-88. [19] NÉRON S,THIBAULT L,DUSSAULT N,et al. Characterization of mononuclear cells remaining in the leukoreduction system chambers of apheresis instruments after routine platelet collection:a new source of viable human blood cells[J]. Transfusion,2007,47(6):1042-1049. [20] JIA Z H,REN Z Y,YE D M,et al.Immune-ageing evaluation of peripheral T and NK lymphocyte subsets in Chinese healthy adults[J]. Phenomics,2023,3(4):360-374. |